Linterpharma SRL
Linterpharma reported total assets of €1.63m at the end of the 2025 financial year (annual accounts filed with the NBB on 23 Jul 2026).
The score of Linterpharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -1 % Total assets -21 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Linterpharma's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 23 Jul 2026
- Year ended 31 Dec 2024filed on 24 Jun 2025
- Year ended 31 Dec 2023filed on 16 Jul 2024
- Year ended 31 Dec 2022filed on 25 Jul 2023
- Year ended 31 Dec 2021filed on 14 Jul 2022
Linterpharma's financial analysis
- Solvency71.3%sector median: 44.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Linterpharma
Linterpharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0426.079.824
- VAT number
- BE0426079824
- Peppol
- Registered · 0208:0426079824 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 26 Jul 1984
- Registered office
- 3350 Linter
- Latest accounts
- 2025 · filed on 23 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Linterpharma (SRL) has been based in Linter since 1984, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 244,707 € and equity of €1.16m; its revenue is not published. Its solvency stands at 71.3%, above the median of its sector (44.2%).
Companies similar to Linterpharma
Companies in the same business, of comparable size and area, outside its group.
- De Magistrale Retail sale of pharmaceutical products Brakel · balance sheet €1.63m
- Lindephar Retail sale of pharmaceutical products Evergem · balance sheet €1.63m
- Pharmacie DU Parvis - Voorplein Apotheek Retail sale of pharmaceutical products Woluwe-Saint-Pierre · balance sheet €1.63m
- Apotheek Gedopt Retail sale of pharmaceutical products Schoten · balance sheet €1.64m
- Devaphar Retail sale of pharmaceutical products Brussels · balance sheet €1.63m
- Centrumapotheek Beerse Retail sale of pharmaceutical products Beerse · balance sheet €1.63m
- Aerts-Janssens Retail sale of pharmaceutical products Schoten · balance sheet €1.64m
- Spypharma Retail sale of pharmaceutical products Forest · balance sheet €1.62m
Frequently asked questions about Linterpharma
What is the revenue of Linterpharma?
Linterpharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Linterpharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0426079824 for Linterpharma, if the company is VAT-registered. Its company number (CBE) is 0426.079.824.
Where is the registered office of Linterpharma?
According to the CBE register, the registered office of Linterpharma is in 3350 Linter.
What is the equity of Linterpharma?
At the close of the 2025 financial year, the equity of Linterpharma amounts to 1,164,959 €, a solvency of 71.3% of total assets.
Who manages Linterpharma?
The register lists 2 active mandates at Linterpharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Linterpharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →